This trial is evaluating whether PB 718 will improve 1 primary outcome and 1 secondary outcome in patients with Healthy Subjects (HS). Measurement will happen over the course of From Group A1 until Group B4. The study duration for each subject in Part A will be approximately 8 weeks. The study duration for each subject in Part B will be approximately 11 weeks..
This trial requires 80 total participants across 11 different treatment groups
This trial involves 11 different treatments. PB 718 is the primary treatment being studied. Participants will be divided into 10 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
Participation is compensated
You will be compensated for participating in this trial.
"The majority of the hs in this study had not had symptoms prior to study enrollment, indicating some degree of subclinical disease in this sample. The most common reason cited for enrollment in these studies was for participation in clinical trials. However, the overall health status and health-related characteristics of the hs did not differ from those of a large, nationally representative database of US adults in terms of most medical conditions, medical utilization, prescription drugs, or socioeconomic status." - Anonymous Online Contributor
"Since hs does not suffer any damage from chemotherapy and radiation therapy, it can only be recommended to perform health evaluations if they are at risk of getting SCC." - Anonymous Online Contributor
"There are many treatments used to treat common conditions. While some treatments may have some benefit, their use varies greatly across studies. Results from a recent paper provides several guidelines for clinicians to use in their practice. By considering the frequency and effectiveness of treatments for individual disorders, clinicians can provide a more consistent care option to their patients. There is a necessity for more research to be conducted that focuses on the effects of treatment on patients and their quality of life." - Anonymous Online Contributor
"The HSR is useful for identifying subjects with asymptomatic diseases or with subclinical diseases, but it should be used only cautiously when evaluating participants with symptomatic diseases." - Anonymous Online Contributor
"Despite an [increasing] number of studies evaluating the generalizability of nonrandomized trials of medical interventions, hs are still frequently used in the United States. The hs issue needs to be tackled by the [research and publishing] community to ensure [that these trials] are scientifically based and justified." - Anonymous Online Contributor
"At least one-third of HSA-SES visits in 2014 were for patients under 55 years, the highest proportion we had seen in our institution over the last 12 years." - Anonymous Online Contributor
"If you have had a hysterectomy and had endometriosis, the UroVysion Pb 718 may help show if the [tubal ligation] in your past is responsible for menstrual irregularities. The UroVysion Pb 718 is NOT available for [menstrual cycle disorders without endometrioses] (without hysterectomy)." - Anonymous Online Contributor
"As the number of clinical trials is increasing, clinicaltrials.gov now offers an exhaustive list of clinical trials, including those specifically designed for healthy subjects. We urge patients and their families alike to consider participation in clinical trials before starting a new treatment regimen. ClinicalTrials.gov (http://wwwnCT01052837-1) also offers clinical trials information, including patient education and resources, as well as links to other lupus and inflammatory disorders clinical trials." - Anonymous Online Contributor
"While the development of bispecific antibodies is a major advance, the development of chimeric antibodies is also of interest. While an antibody to a cancer specific antigen is preferable, an antibody that binds to a T cell costimulatory molecule is feasible. In the future, the search for a monospecific antibody to a single CD3 antigen should broaden our repertoire of T cell costimulatory molecules, and further our knowledge of tumor and T cells." - Anonymous Online Contributor
"Results from a recent paper of these studies indicate that a high dose of oral vitamin D3 with or without vitamin D3 with UVB phototherapy should increase insulin sensitivity. Higher dose of vitamin D3 may decrease insulin resistance in hs. We expect these high‐quality trials would be included in any clinical practice guidelines or guidelines on hs in the future." - Anonymous Online Contributor
"pb 718 was well tolerated and was effective in reducing serum ferritin in patients with iron overload. A randomized trial of pb 718 in patients with chronic hepatitis B is therefore desirable." - Anonymous Online Contributor